Fact CheckerSign in

NCT06598813Completed

Pediatric Headche Assessment Using HIT 6

Pediatric Headche Assessment Comparing PedMidas and HIT 6 Questionnaires

Source: ClinicalTrials.gov · Last updated 19 Sept 2024

Brief summary (registry, in English)

The study is a prospective cohort study. The study population will include 100 children aged 6-18 years suffering from headaches who visited the Pediatric Neurology Clinic at Bnai Zion Medical Center and completed both the PED-MIDAS and HIT-6 questionnaires, starting from November 2022 until the end of the study period. Data will be collected from medical records and from the two questionnaires completed by the children during their clinic visit.

Status (registry)
Completed
Study type
Observational
Enrollment
100 (actual)
First submitted
12 Sept 2024
Start date
1 Dec 2022
Primary completion date
1 Aug 2024
Lead sponsor
Bnai Zion Medical Center
Diseases
Migraine
NCT number
NCT06598813

What you commit to

  • Study type: Observational
  • Participants enrolled: 100
  • From 1 Dec 2022 to the primary completion date, 1 Aug 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Children with shoreter headaches.
  • Children who are not able to fill the questionnaire

Who the study is looking for

  • Chldern age 6-18 years with headache for at least 3 months.
  • Children able to fill the questionnaire

Age in the registry: 6 years to 18 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Bnai Zion Medical Cemter
Coordinator of this site? Confirm its status
HaifIsraelUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.